Jump Financial LLC Increases Position in Incyte Co. (NASDAQ:INCY)

Jump Financial LLC grew its position in Incyte Co. (NASDAQ:INCY - Free Report) by 1,562.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 99,448 shares of the biopharmaceutical company's stock after acquiring an additional 93,465 shares during the quarter. Jump Financial LLC's holdings in Incyte were worth $6,244,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Larson Financial Group LLC lifted its stake in Incyte by 4,220.0% in the fourth quarter. Larson Financial Group LLC now owns 432 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 422 shares during the last quarter. Turtle Creek Wealth Advisors LLC purchased a new position in Incyte during the 4th quarter valued at $31,000. Livforsakringsbolaget Skandia Omsesidigt grew its position in Incyte by 157.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 772 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 472 shares during the last quarter. Allworth Financial LP increased its stake in Incyte by 40.0% in the fourth quarter. Allworth Financial LP now owns 802 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 229 shares during the period. Finally, NBC Securities Inc. bought a new stake in shares of Incyte during the third quarter worth $83,000. Institutional investors own 96.97% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on INCY shares. Cantor Fitzgerald assumed coverage on shares of Incyte in a research note on Tuesday, April 23rd. They issued a "neutral" rating on the stock. TD Cowen lowered their price target on Incyte from $88.00 to $80.00 and set a "buy" rating for the company in a report on Wednesday, May 1st. JMP Securities downgraded Incyte from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 14th. Stifel Nicolaus lifted their target price on Incyte from $67.00 to $68.00 and gave the company a "hold" rating in a research report on Wednesday, February 14th. Finally, William Blair reissued an "outperform" rating on shares of Incyte in a research report on Tuesday, February 6th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $74.93.

Incyte Stock Down 0.8 %

INCY traded down $0.44 during trading on Friday, hitting $53.06. The stock had a trading volume of 1,505,329 shares, compared to its average volume of 2,118,308. The stock has a 50 day simple moving average of $55.49 and a two-hundred day simple moving average of $57.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.43 and a current ratio of 3.47. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $67.36. The company has a market capitalization of $11.91 billion, a PE ratio of 16.08, a PEG ratio of 1.33 and a beta of 0.69.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing analysts' consensus estimates of $1.15 by ($0.09). Incyte had a return on equity of 12.83% and a net margin of 19.78%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the business earned $0.44 EPS. The firm's revenue for the quarter was up 9.3% compared to the same quarter last year. On average, research analysts predict that Incyte Co. will post 3.54 earnings per share for the current year.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.